# Rapid urinary lipoarabinomannan test with laboratory-level sensitivity for tuberculosis detection: a performance evaluation

## TL;DR

A new rapid urine test for tuberculosis shows better performance than existing methods, offering a promising non-sputum diagnostic tool.

## Contribution

The PF-LAM test demonstrates higher sensitivity and precision than existing rapid and lab-based TB tests, with minimal variability between batches.

## Key findings

- PF-LAM showed 33.8% sensitivity compared to 5.5% for AlereLAM in preclinical testing.
- PF-LAM achieved 58% sensitivity in diagnostic accuracy studies, outperforming EclLAM's 42%.
- PF-LAM exhibited high precision and minimal lot-to-lot variability.

## Abstract

Developing rapid, non-sputum-based tests is a global priority to improve the diagnosis and timely treatment of tuberculosis (TB). In this study, we evaluated the detection limit, precision, stability, and lot-to-lot variation of a next-generation rapid diagnostic test (RDT), the plasmonic fluor (PF)-enhanced urinary lipoarabinomannan lateral flow assay (PF-LAM). We also assessed the diagnostic performance of PF-LAM, Alere Determine TB LAM Ag (AlereLAM), and electrochemiluminescence LAM assay (EclLAM), a highly sensitive laboratory-based test by comparing with microbiology reference standard (MRS) that includes molecular testing (Xpert MTB/RIF) and culture. Two sub-studies were conducted using banked urine samples. First, a preclinical study involving 399 well-characterized urine samples was conducted to determine assay cutoff and assess PF-LAM performance compared with Alere LAM. Second, a diagnostic accuracy assessment study was conducted using 77 blinded samples to compare the performance of PF-LAM to EclLAM. In the preclinical study, when compared with MRS, the AlereLAM showed a sensitivity of 5.5% (95% CI: 3.1%–9.6%) and a specificity of 98.5% (95% CI: 95.6%–99.6%), while PF-LAM exhibited a sensitivity of 33.8% (95% CI: 27.4%–40.6%) and the same specificity of 98.5% (95% CI: 95.6%–99.6%). In the diagnostic accuracy study, when compared with MRS, PF-LAM achieved a sensitivity of 58% (95% CI: 41%–73%) and a specificity of 98% (95% CI: 88%–100%), while EclLAM showed a sensitivity of 42% (95% CI: 27%–59%) and a specificity of 95% (95% CI: 85%–99%). Overall, PF-LAM demonstrated better analytical and diagnostic sensitivity compared with EclLAM and significantly better performance compared with AlereLAM, while exhibiting high precision and minimal lot-to-lot variability.

To the best of our knowledge, this study uniquely reports a rapid diagnostic test, plasmonic fluor-enhanced urinary lipoarabinomannan lateral flow assay (PF-LAM), outperforming an electrochemiluminescence-based laboratory assay. PF-LAM demonstrated promising analytical and diagnostic performance with minimal lot-to-lot variability, positioning it as a helpful tool for non-sputum tuberculosis diagnostics.